Octagon Capital Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Octagon Capital Advisors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,450,000	Closed	-$29.2M	–	30
2026 Q1	$29.2M	Buy	1,450,000 +176,667	+14%	+$2.85M	3.23%	12
2025 Q4	$20.6M	Hold	1,273,333	–	–	2.5%	16
2025 Q3	$15.5M	Hold	1,273,333	–	–	2.35%	16
2025 Q2	$14.4M	Sell	1,273,333 -96,667	-7%	-$1.18M	3.16%	15
2025 Q1	$15.8M	Hold	1,370,000	–	–	3.06%	11
2024 Q4	$11.6M	Buy	+1,370,000	New	+$14.2M	1.91%	23

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Octagon Capital Advisors's KALV Position: Q2 2026 in Review

Octagon Capital Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,450,000 shares — an estimated $29.2M sold.

Octagon Capital Advisors first reported a position in KALV in Q4 2024 and held it in 6 quarters. The position peaked at $29.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Octagon Capital Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Octagon Capital Advisors sold 1,450,000 KalVista Pharmaceuticals shares in Q2 2026, an estimated $29.2M.
Octagon Capital Advisors first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Octagon Capital Advisors's KalVista Pharmaceuticals position peaked at $29.2M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.